Macquarie ups the ante on Dixon Tech, but the Street remains divided on the Vivo deal

As Dixon Technologies navigates regulatory hurdles for its high-stakes Vivo partnership, global brokerages remain sharply split on the company's future trajectory.

Dixon Technologies finds itself at the centre of a heated debate on Dalal Street. While the company’s stock has seen a stellar 24% rally since late March, investors are now grappling with conflicting signals from global brokerages regarding whether this momentum has legs or is simply overstretched.

Macquarie has emerged as the latest bull, maintaining an 'Outperform' rating on the electronics manufacturing services (EMS) giant with a target price of ₹15,000. For the brokerage, the potential approval of the joint venture with Vivo Mobile India is a game-changer. Even as Dixon management guided for a revenue of ₹560 billion by FY27—a figure that notably excludes contributions from the Vivo venture and the PLI 2.0 scheme—Macquarie views these two initiatives as the primary catalysts that could significantly bolster the firm’s medium-term localisation strategy.

The Regulatory Reality Check

Despite the market optimism, the path to expansion isn't entirely clear. In response to a formal query from the National Stock Exchange, Dixon clarified that while a binding term sheet was signed with Vivo back in December 2024, the transaction is still waiting on definitive agreements and, crucially, statutory approvals. The company’s growth narrative is heavily pinned on these regulatory nods, and until the paperwork clears, the excitement remains speculative.

This uncertainty hasn't stopped the brokerage community from taking sides. JPMorgan, for instance, has echoed the bullish sentiment with an 'Overweight' rating and a ₹12,700 target, banking on the Vivo venture to reshape the company’s outlook. However, a significant portion of the Street is urging caution. CLSA recently turned the tide by downgrading Dixon to 'Underperform', maintaining a conservative ₹10,400 target.

Why it matters

The divergence in opinion reflects a deeper anxiety about the structural health of the electronics manufacturing sector. Bears like CLSA argue that the recent surge in the dixon technologies share price has been excessive, cautioning that elevated memory prices could squeeze demand for Indian smartphones. Furthermore, there are genuine concerns regarding the company’s organic growth, with some analysts fearing that the domestic market is nearing a saturation point.

Ultimately, the company is at a crossroads. Dixon has successfully positioned itself as a proxy for India’s manufacturing ambitions, but its next phase of scaling requires more than just government incentives. It needs successful execution on massive, complex partnerships. Whether the current valuation is justified will depend on how quickly these pending regulatory approvals translate into actual production lines. For now, with 22 'Buy' ratings against seven 'Sell' recommendations among 32 analysts, the optimism still has the upper hand, even if the skeptics are growing louder.